Acglo stock hits 52-week low at 17.76 USD

LeMaitre Vascular Inc (LMAT) stock plummeted to a 52-week low of $78.22, marking a significant 34% drop from its 52-week high of $118.01. This challenging year has seen the company's stock decline by 12.65% over the past year, with a particularly sharp 18% drop over the last six months. The decline is influenced by broader market fluctuations and sector-specific issues that have affected the firm's performance.

Analysts have lowered their earnings estimates for the upcoming period, with 4 revisions noted in InvestingPro data. Despite this, the company boasts a solid record of consistently raising dividends for 16 years and holds a high financial health score. Pro Research Report indicates the stock could be undervalued at its current price, offering further analysis through its platform.

The company released its Q3 earnings, reporting $68 million in sales, slightly surpassing the estimated $67.74 million. Organic revenue grew 12%, with Americas revenue reaching $42.7 million, up 9% year-over-year, and international revenue up 17.5% excluding forex effects. Adjusted earnings per share of $0.65 fell short of the expected $0.69.

Wells Fargo adjusted its price target from $94 to $86 with an Equal Weight rating, while Citizens revised its target from $127 to $110, maintaining a Market Outperform rating. The earnings report highlighted robust demand for grafts, shunts, and biologic products, but the slight miss in adjusted EPS and EBITDA by 6% and 1% respectively led to these adjustments.